Walvax Initiates Phase I Trial of Lyophilized Shingles mRNA Vaccine – First‑in‑Class Herpes Zoster Candidate Co‑Developed with Fudan University and RQ Biotech

Walvax Biotechnology Co., Ltd. (SHE: 300142) announced the official initiation of a Phase I clinical trial of its lyophilized herpes zoster (shingles) mRNA vaccine, co‑developed with Fudan University and RQ…

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.